Microbiome and neurodegeneration
| Educator
22nd Jun, 2021Quick read

This post is specifically for health practitioners. Create a free account

Alternatively, view general public info.

Learn more about vital.ly

Microbiome and neurodegeneration


A recent study has established a link between specific gut bacteria species and the physical manifestations of neurodegenerative diseases (1).

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are characterised by problems with the way proteins are handled in the body. The misfolding and accumulation of proteins in the brain often results in the loss of tissue function that promotes disease progression (2). Millions of adults around the world suffer from these “protein conformational diseases” (PCDs), resulting in enormous financial and social burdens on the individuals themselves as well as their carers (3). There is still no effective treatment or cure for PCDs, and the cause is still largely unknown (4).

Factors such as age, diet, stress, trauma, toxins, infections, or antibiotics, have been shown to increase the risk of PCDs. These triggers are also associated with changes in the microbiome which suggests that bacteria may contribute to the pathogenesis of PCDs. However, the relationship between the microbiome and disease progression remains poorly defined.

Evidence has established a link between human gut dysbiosis or direct intestinal infection and exacerbation of PCDs (5,6,7). Commensal residents of the human microbiota, specifically those involved in the synthesis of short-chain fatty acids (SCFAs) such as butyrate, are beneficial in brain disorders (8).

Environmental factors and the complexity of the human microbiome make the complex study of the effect of the microbiome on PCDs difficult (9). This latest study was carried out on C. elegans and showed that specific species of bacteria play a role in the development of PCDs. Commensal butyrate-producing bacteria can counteract these pathogenic strains (1).


Pathogenic strains

Among all of the strains that were tested, Klebsiella spp. and P. aeruginosa were the most potent inducers of misfolded protein aggregation. Both of these species are ubiquitous in the environment, and multidrug-resistant strains of these bacteria are often associated with nosocomial and opportunistic infections (10). While these strains are often associated with infections, they are also  present in the intestines of healthy individuals, which may possibly support their contribution to neurodegenerative diseases (11,12). In fact, both of these microbes have recently been associated with neurodegenerative diseases in humans (13,14). The increasing prevalence of antibiotic resistance among Klebsiella spp. and P. aeruginosa strains may specifically encourage their growth within the human microbiome during antibiotic treatment while decreasing the abundance of beneficial bacteria. Population-based studies of patients with PD and ALS support this hypothesis, revealing that a history of antibiotic treatment is associated with an elevated risk for these diseases (15,16). However, more research is required before we can understand what, if any, connection there is between antibiotic resistance and neurodegenerative diseases.

Another notable strain that induced aggregation by more than three-fold is P. mirabilis. This gram-negative bacterium is part of human commensal microbiota but can also become an opportunistic pathogen, most often leading to urinary tract infections, and eventually, bacteraemia (17).

A surprising and interesting finding from this study is the fact that the offspring of affected C. elegans also showed increased protein aggregation, even though these offspring never encountered the bacteria originally associated with the condition. This suggests that these bacteria generate some sort of a signal that can be passed along to the next generation.



The depletion of butyrate-producing bacteria in the gut establishes an environment in which pathogenic bacteria can flourish (18). In addition, butyrate itself has been found to suppress the growth of pathogenic bacteria and was shown to protect against neurodegeneration (19,20). SCFA-producing bacteria are common residents of the human gut microbiota. Many of these bacteria, such as those belonging to the Firmicutes phylum, are known to produce butyrate (21). Butyrate has been demonstrated to provide numerous health benefits against a variety of ailments, and neurodegenerative diseases are no exception (20). Results from this recent study demonstrate that butyrate can suppress protein aggregation and the associated toxicity when supplied exogenously or produced by intestinal bacteria (1).

Results also indicate that butyrate may inhibit bacteria-induced aggregation by activating protective stress responses, in particular, oxidative stress responses. Bacteria are known to trigger oxidative stress, which can contribute to protein aggregation (22). It is possible that various bacteria introduce different levels of oxidative stress and the strongest contributors affect host protein homeostasis, consequently leading to misfolding and aggregation of proteins. In fact, oxidative stress is one of the major contributors to PCDs (23).



The results in this study demonstrate that bacteria alone do not cause major toxicity in control animals that do not express metastable aggregation-prone proteins, which indicates that other factors are at play in the aetiology of neurodegenerative diseases. However, in those that do express aggregate-prone proteins, gut bacteria play a role in disease progression.



These latest results indicate that endogenous butyrate synthesised by butyrate-producing bacteria can enhance host protein homeostasis and suppress protein misfolding in the brain. Butyrate and butyrate-producing bacteria also show potential benefits in the suppression of bacteria-induced protein-associated toxicity. This highlights the importance of having a balance between commensal butyrate-producing and intestinal pathogenic microbes.

1Walker AC, Bhargava R, Vaziriyan-Sani AS, Pourciau C, Donahue ET, Dove AS, et al. Colonization of the Caenorhabditis elegans gut with human enteric bacterial pathogens leads to proteostasis disruption that is rescued by butyrate. PLoS Pathog. 2021 May;17(5):e1009510.
2Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003 Jan;4(1):49–60.
3El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders. J Alzheimers Dis. 2019;70(2):323–41.
4Durães F, Pinto M, Sousa E. Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals (Basel). 2018 May 11;11(2).
5Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015 Mar;30(3):350–8.
6Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol. 2018 Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition&Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S68–70.
7Gerhardt S, Mohajeri MH. Changes of Colonic Bacterial Composition in Parkinson’s Disease and Other Neurodegenerative Diseases. Nutrients. 2018 Jun 1;10(6).
8Zhu S, Jiang Y, Xu K, Cui M, Ye W, Zhao G, et al. The progress of gut microbiome research related to brain disorders. J Neuroinflammation. 2020 Jan 17;17(1):25.
9Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature. 2020 Jun;582(7810):89–94.
10Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008 Apr 15;197(8):1079–81.
11Zou Y, Xue W, Luo G, Deng Z, Qin P, Guo R, et al. 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses. Nat Biotechnol. 2019 Feb;37(2):179–85.
12Estepa V, Rojo-Bezares B, Torres C, Sáenz Y. Faecal carriage of Pseudomonas aeruginosa in healthy humans: antimicrobial susceptibility and global genetic lineages. FEMS Microbiol Ecol. 2014 Jul;89(1):15–9.
13Steenblock D, Ikrar T, Antonio A, Wardaningsih E, Azizi M. Amyotrophic Lateral Sclerosis (ALS) Linked to Intestinal Microbiota Dysbiosis & Systemic Microbial Infection in Human Patients: A Cross-Sectional Clinical Study. Int J Neurodegener Dis. 2018 Dec 31;1(003).
14Haran JP, Bhattarai SK, Foley SE, Dutta P, Ward DV, Bucci V, et al. Alzheimer’s Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway. mBio. 2019 May 7;10(3).
15Mertsalmi TH, Pekkonen E, Scheperjans F. Antibiotic exposure and risk of Parkinson’s disease in Finland: A nationwide case-control study. Mov Disord. 2020 Mar;35(3):431–42.
16Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019 Nov;26(11):1355–61.
17Chen C-Y, Chen Y-H, Lu P-L, Lin W-R, Chen T-C, Lin C-Y. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. J Microbiol Immunol Infect. 2012 Jun;45(3):228–36.
18Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017 Aug 11;357(6351):570–5.
19Sorbara MT, Dubin K, Littmann ER, Moody TU, Fontana E, Seok R, et al. Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification. J Exp Med. 2019 Jan 7;216(1):84–98.
20Zhang Y-G, Wu S, Yi J, Xia Y, Jin D, Zhou J, et al. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. Clin Ther. 2017 Feb;39(2):322–36.
21Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017 Jan;19(1):29–41.
22Mohri-Shiomi A, Garsin DA. Insulin signaling and the heat shock response modulate protein homeostasis in the Caenorhabditis elegans intestine during infection. J Biol Chem. 2008 Jan 4;283(1):194–201.
23Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009 Mar;7(1):65–74.